WAM
TEVA icon

Wealthspire Advisors (Maryland)’s Teva Pharmaceuticals TEVA Stock Holding History

Wealthspire Advisors (Maryland)’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-2,332
Closed -$37K – 1861
2019
Q1 		$37K Sell
2,332
-500
-18% -$8.82K ﹤0.01% 1028
2018
Q4 		$44K Sell
2,832
-414
-13% -$8.49K ﹤0.01% 918
2018
Q3 		$70K Sell
3,246
-720
-18% -$16.7K 0.01% 835
2018
Q2 		$96K Buy
3,966
+873
+28% +$17.8K 0.01% 724
2018
Q1 		$53K Buy
3,093
+455
+17% +$8.88K 0.01% 957
2017
Q4 		$50K Sell
2,638
-697
-21% -$10.5K ﹤0.01% 1015
2017
Q3 		$59K Sell
3,335
-376
-10% -$8.46K 0.01% 912
2017
Q2 		$123K Buy
3,711
+94
+3% +$2.91K 0.01% 610
2017
Q1 		$116K Buy
3,617
+261
+8% +$8.91K 0.02% 551
2016
Q4 		$122K Sell
3,356
-1,367
-29% -$54.6K 0.02% 515
2016
Q3 		$217K Sell
4,723
-20
-0.4% -$1.04K 0.03% 358
2016
Q2 		$238K Buy
4,743
+1,150
+32% +$61.2K 0.04% 320
2016
Q1 		$192K Sell
3,593
-792
-18% -$46.5K 0.03% 374
2015
Q4 		$288K Buy
+4,385
New +$271K 0.05% 262

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wealthspire Advisors (Maryland)'s TEVA Position: Q2 2019 in Review

Wealthspire Advisors (Maryland) sold out of Teva Pharmaceuticals (TEVA) in Q2 2019, closing a stake of 2,332 shares — an estimated $37K sold.

Wealthspire Advisors (Maryland) first reported a position in TEVA in Q4 2015 and held it in 14 quarters. The position peaked at $288K in Q4 2015. 452 funds tracked by Wall St. Rank hold TEVA as of Q2 2019.

  • Wealthspire Advisors (Maryland) reported no remaining Teva Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Wealthspire Advisors (Maryland) sold 2,332 Teva Pharmaceuticals shares in Q2 2019, an estimated $37K.
  • Wealthspire Advisors (Maryland) first reported a position in Teva Pharmaceuticals in Q4 2015 and held it in 14 quarters.
  • Wealthspire Advisors (Maryland)'s Teva Pharmaceuticals position peaked at $288K in Q4 2015.
  • 452 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2019.

Based on Wealthspire Advisors (Maryland)'s 13F filing for Q2 2019, filed 12 Aug 2019.